|
|
|
Volumn 4, Issue 6, 2002, Pages 601-605
|
|
Technology evaluation: ALVAC-CEA/B7.1, Aventis Pasteur/Therion
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALVAC CEA B7 1;
ANTINEOPLASTIC AGENT;
B7 ANTIGEN;
CANCER VACCINE;
CARCINOEMBRYONIC ANTIGEN;
CD28 ANTIGEN;
CD4 ANTIGEN;
CD8 ANTIGEN;
CD86 ANTIGEN;
DNA VACCINE;
IMMUNOGLOBULIN G;
INTERCELLULAR ADHESION MOLECULE 1;
LIVE VACCINE;
LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1;
MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;
MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;
NEUTRALIZING ANTIBODY;
PLACEBO;
RECOMBINANT VACCINE;
UNCLASSIFIED DRUG;
VACCINIA VACCINE;
VIRUS VECTOR;
ANTIGEN EXPRESSION;
ANTIGEN PRESENTING CELL;
ARTICLE;
AUTOIMMUNITY;
BIOTECHNOLOGY;
CANCER IMMUNOTHERAPY;
CELL SURFACE;
CELLULAR IMMUNITY;
CLINICAL TRIAL;
COLORECTAL TUMOR;
DOSE RESPONSE;
DRUG EFFICACY;
DRUG INDICATION;
DRUG INDUSTRY;
DRUG METABOLISM;
DRUG POTENTIATION;
DRUG RESEARCH;
DRUG SAFETY;
DRUG SYNTHESIS;
DRUG TARGETING;
FLU LIKE SYNDROME;
HUMAN;
HUMORAL IMMUNITY;
INJECTION PAIN;
LUNG TUMOR;
MALIGNANT NEOPLASTIC DISEASE;
MYALGIA;
NONHUMAN;
POXVIRUS;
STRUCTURE ACTIVITY RELATION;
TOXICITY TESTING;
TUMOR CELL;
VACCINIA VIRUS;
VIRAL GENE DELIVERY SYSTEM;
VIRUS RECOMBINANT;
ANIMALS;
CANCER VACCINES;
CLINICAL TRIALS, PHASE I;
COLORECTAL NEOPLASMS;
DRUG EVALUATION;
HUMANS;
LUNG NEOPLASMS;
TECHNOLOGY, PHARMACEUTICAL;
VACCINES, SYNTHETIC;
POXVIRIDAE;
VACCINIA VIRUS;
|
|
EID: 0036923946
PISSN: 14648431
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (5)
|
|
References (0)
|
